FDA Says Impax Parkinson's Drug Not Approvable
Posted on: Thursday, 9 March 2006, 21:00 CST
Impax Laboratories has received a non-approvable letter from the FDA concerning its new drug application for Vadova, the company's investigational treatment for Parkinson's disease.
According to the company, the letter cites several deficiencies in the application, including observations resulting from an FDA inspection of the contract laboratory employed by Impax to perform bioequivalence studies.
Impax is now hoping to schedule a meeting with the FDA to review the comments in detail. The company said that it is currently unable to predict when or if Vadova might be available for commercial launch.
"We are disappointed with this development and we will work diligently with the FDA and the contract laboratory to provide the additional data required for approval as fast as prudently possible. We followed the study design described in our investigational new drug application and we believe the results obtained not only present a valuable product for the patient but are within the regulatory requirements," commented Dr Larry Hsu, Impax' president.
Source: Datamonitor
Related Articles
- Impax Receives FDA Non-Approvable Letter for Vadova
- IMPAX Receives FDA Non-Approvable Letter for Vadova(R); Company Considering Options
- IMPAX Files Amendment to Vadova(TM) NDA
- IMPAX Receives FDA Approval for Generic Version of Colestid(R); Global Pharmaceuticals Division to Launch
- IMPAX Receives FDA Approval for Generic Version of SALAGEN(R) Tablets; Global Pharmaceuticals Division to Launch
- IMPAX Receives FDA Non-Approvable Letter for Vadova; Company to Request Meeting With FDA
- FDA Law Enforcement: Critical to Product Safety
- IMPAX Signs Exclusive Supply and Distribution Agreement With DAVA Pharmaceuticals for Oxycodone Hydrochloride Extended Release Tablets
- IMPAX Prevails in Alza's Lawsuit Related to Generic Version of Ditropan XL
 |
 |
User Comments (0)
RSS Feeds